<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03908138</url>
  </required_header>
  <id_info>
    <org_study_id>ShandongPH03</org_study_id>
    <nct_id>NCT03908138</nct_id>
  </id_info>
  <brief_title>RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma</brief_title>
  <official_title>RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Provincial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple myeloma (MM) is a common malignant hematology disease. The development of proteasome&#xD;
      inhibitors (PIs) and immunomodulatory drugs (IMiDs) significantly improved the survival of MM&#xD;
      patients. IMiDs have multiple effects in MM therapy. Except for direct cytotoxicity, IMiDs&#xD;
      also play a variety of immune regulatory roles. Lenalidomide, a kind of IMiDs, was usually&#xD;
      used in the therapy of relapsed/refractory MM. The efficacy and safety of RDD (lenalidomide,&#xD;
      pegylated liposomal doxorubicin, dexamethasone) in newly diagnosed patients with MM still&#xD;
      needs to be further validated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The therapy regimens of MM were very limited before 2000, mainly including VAD (vincristine,&#xD;
      doxorubicin, dexamethasone), methylpheniram, corticosteroids and autologous stem cell&#xD;
      transplantation (ASCT). The development of proteasome inhibitors (PIs) and immunomodulatory&#xD;
      drugs (IMiDs) in the 2000's significantly improved the survival of MM patients. Combined&#xD;
      chemotherapy containing new drugs has become the first-line therapy for the treatment of&#xD;
      newly diagnosed MM patients.&#xD;
&#xD;
      In addition to direct cytotoxicity, IMiDs also play a variety of immune regulatory roles. The&#xD;
      effects on immune system include reducing TNF-α, IL-1β, IL-6 and IL-12, increasing production&#xD;
      of IL-2 and IFN-γ, increasing T cell initiation, enhancing the absorption of tumor antigen by&#xD;
      dendritic cells (DCs), enhancing the efficiency of antigen presentation, inhibiting&#xD;
      regulatory T cells (Treg), and enhancing the activity of natural killer cells (NK) and NKT&#xD;
      cells. Lenalidomide, a kind of IMiDs, also have the effects on osteoclasts, which are&#xD;
      important in bone disease in MM patients.&#xD;
&#xD;
      In 2006, the combination of lenalidomide and dexamethasone (RD) was approved in the United&#xD;
      States for the treatment of relapsed/refractory MM. The RD regimen was approved for the&#xD;
      treatment of newly diagnosed MM patients in 2015. Four lenalidomide-containing triple drug&#xD;
      regimens were approved for the treatment of relapsed/refractory MM from 2015 to 2016.&#xD;
      However, the application of lenalidomide-containing triple drug regimens in newly diagnosed&#xD;
      patients with multiple myeloma needs to be further validated. Therefore, we designed the&#xD;
      randomized controlled clinical study and aimed to compare the efficacy and safety between RDD&#xD;
      (lenalidomide, pegylated liposomal doxorubicin, dexamethasone) and VDD (bortezomib, pegylated&#xD;
      liposomal doxorubicin, dexamethasone) in newly diagnosed patients with MM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The patients will be randomized either receiving RDD or receiving VDD therapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>no mask.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>complete response (CR)</measure>
    <time_frame>At 8 months</time_frame>
    <description>meeting the standard IMWG response criteria (CR and VGCR) of NCCN guidelines (Version2. 2019)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>partial remission (PR)</measure>
    <time_frame>At 8 months</time_frame>
    <description>meeting the standard IMWG response criteria (PR) of NCCN guidelines (Version2. 2019)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progressive free survival</measure>
    <time_frame>At 3 months, 5 months, 8 months, 12 months, 18 months, 24 months and 36 months</time_frame>
    <description>the length of time during and after the treatment of MM that a patient lives with the disease but it does not get worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>At 3 months, 5 months, 8 months, 12 months, 18 months, 24 months and 36 months</time_frame>
    <description>the percentage of MM patient who are alive after 3 years.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Side effects</measure>
    <time_frame>At 3 months, 5 months and 8 months</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Efficacy</condition>
  <condition>Safety</condition>
  <arm_group>
    <arm_group_label>RDD group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lenalidomide: 25mg, po, d1-21， Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20-40mg, po, d1，d8，d15，d22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VDD group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bortezomib:1.3mg/m2，ih，d1，d4，d8，d11 Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20 mg, ivgtt, d1, 2, 4, 5, 8, 9, 11,12</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDD</intervention_name>
    <description>Lenalidomide: 25mg, po, d1-21， Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20-40mg, po, d1，d8，d15，d22</description>
    <arm_group_label>RDD group</arm_group_label>
    <other_name>RDD group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VDD</intervention_name>
    <description>Bortezomib:1.3mg/m2，ih，d1，d4，d8，d11 Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20 mg, ivgtt, d1, 2, 4, 5, 8, 9, 11,12</description>
    <arm_group_label>VDD group</arm_group_label>
    <other_name>VDD group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of symptomatic (active) MM;&#xD;
&#xD;
          -  Ages ≥18 years old, ≤65 years old;&#xD;
&#xD;
          -  ECOG score: 0-2;&#xD;
&#xD;
          -  Liver function: transaminase≤2.5×upper limit of normal value，bilirubin≤1.5×upper limit&#xD;
             of normal value;&#xD;
&#xD;
          -  Renal function: serum creatinine is 44-176 mmol/L;&#xD;
&#xD;
          -  LVEF≥50%;&#xD;
&#xD;
          -  New York Heart Association (NYHA) heart function classification is I-II grade;&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe complications or severe infection;&#xD;
&#xD;
          -  Severe heart disease history, including ventricular tachycardia (VT), atrial&#xD;
             fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure&#xD;
             (CHF), coronary heart disease patients needed therapy;&#xD;
&#xD;
          -  Severe allergic constitution, or those who are allergic to or intolerant of drug&#xD;
             composition in chemotherapy regimens; with other malignant tumors in the past 5 years;&#xD;
&#xD;
          -  Patients participate in other clinical studies;&#xD;
&#xD;
          -  Patients are not suitable for the study;&#xD;
&#xD;
          -  Other contraindications for ASCT therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Wang, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Provincial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin Wang, PhD, MD</last_name>
    <phone>+86-531-68778331</phone>
    <email>xinw@sdu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xin Liu, PhD, MD</last_name>
    <phone>+86-15168889791</phone>
    <email>13518611662@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Hematology, Provincial Hospital Affiliated to Shandong University</name>
      <address>
        <city>Jin'an</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Wang, MD, PHD</last_name>
      <phone>86-531-68778331</phone>
      <email>xinw007@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xin Liu, MD,PHD</last_name>
      <phone>86-531-68778331</phone>
      <email>13518611662@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Wang Xin</investigator_full_name>
    <investigator_title>Director of Hematology</investigator_title>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

